LAG-3 in cancer immunotherapy

Current Topics in Microbiology and Immunology

Volumn 344, Issue 1, 2010, Pages 269-278

  Goldberg, Monica V ^a   Drake, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anergy; CD4 lymphocyte; CD8 lymphocyte; Checkpoint; LAG 3; Tolerance; Treg; Tumor immunology

Indexed keywords

DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; IMP 321; INFLUENZA VACCINE; LAG 3 IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; OVALBUMIN; PROTEIN LAG 3; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; CD223 ANTIGEN; LEUKOCYTE ANTIGEN;

ANTIGEN BINDING; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG SCREENING; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPHOCYTE FUNCTION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; SARCOMA; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ANIMAL; CD4+ T LYMPHOCYTE; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84862865552     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82-2010-114     Document Type: Article

References (45)

1. Andreae S, Piras F et al (2002) Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol 168:3874-3880 (Pubitemid 34298389)
2. Angevin E, Kremer F et al (1997) Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer 72:431-440 (Pubitemid 27325870)
3. Annunziato F, Manetti R et al (1996) Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production. FASEB J 10:769-776
4. Annunziato F, Manetti R et al (1997) Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. Eur J Immunol 27:2239-2244 (Pubitemid 27404306)
5. Baixeras E, Huard B et al (1992) Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 176:327-337
6. Blackburn SD, Shin H et al (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10:29-37
7. Brignone C, Grygar C et al (2007a) IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study. Vaccine 25:4641-4650 (Pubitemid 46755458)
8. Brignone C, Grygar C et al (2007b) IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines 5:5
9. Brignone C, Escudier B et al (2009) A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15:6225-6231
10. Brignone C, Gutierrez M et al (2010) First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8:71
11. Camisaschi C, Casati C et al (2010) LAG-3 expression defines a subset of CD4(+)CD25(high) Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 184:6545-6551
12. Cappello P, Triebel F et al (2003) LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice, 1. Cancer Res 63:2518-2525 (Pubitemid 36605192)
13. Demeure CE, Wolfers J et al (2001) T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts 1. Eur J Cancer 37:1709-1718 (Pubitemid 32778620)
14. Dijkstra JM, Somamoto T et al (2006) Identification and characterization of a second CD4-like gene in teleost fish. Mol Immunol 43:410-419 (Pubitemid 41740429)
15. El MS, Triebel F (2000) A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol 164:5583-5589 (Pubitemid 30389797)
16. Fleury S, Lamarre D et al (1991) Mutational analysis of the interaction between CD4 and class II MHC: class II antigens contact CD4 on a surface opposite the gp120-binding site. Cell 66:1037-1049 (Pubitemid 121001735)
17. Gandhi MK, Lambley E et al (2006) Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108:2280-2289 (Pubitemid 44497511)
18. Grosso JF, Kelleher CC et al (2007) LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems. J Clin Invest 117:3383-3392 (Pubitemid 350096994)
19. Grosso JF, Goldberg MV et al (2009) Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 182:6659-6669
20. Hannier S, Triebel F (1999) The MHC class II ligand lymphocyte activation gene-3 is codistributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes. Int Immunol 11:1745-1752 (Pubitemid 29533089)
21. Huang CT, Workman CJ et al (2004) Role of LAG-3 in regulatory T cells. Immunity 21:503-513 (Pubitemid 39370506)
22. Huard B, Gaulard P et al (1994) Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 39:213-217 (Pubitemid 24014846)
23. Huard B, Prigent P et al (1995) CD4/major histocompatibility complex class II interaction analyzed with CD4-and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 25:2718-2721
24. Huard B, Mastrangeli R et al (1997) Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci USA 94:5744-5749 (Pubitemid 27241841)
25. Huard B, Tournier M et al (1998) LAG-3 does not define a specific mode of natural killing in human. Immunol Lett 61:109-112 (Pubitemid 28260984)
26. Joosten SA, van Meijgaarden KE et al (2007) Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 104:8029-8034 (Pubitemid 47185870)
27. Kapp JA, Bucy RP (2008) CD8+ suppressor T cells resurrected. Hum Immunol 69:715-720
28. Kisielow M, Kisielow J et al (2005) Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells 2. Eur J Immunol 35:2081-2088 (Pubitemid 41015047)
29. Li N, Wang Y et al (2007) Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 26:494-504 (Pubitemid 46160949)
30. Liang B, Workman C et al (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180:5916-5926
31. Macon-Lemaitre L, Triebel F (2005) The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 115:170-178 (Pubitemid 40733402)
32. Matsuzaki J, Gnjatic S et al (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 107:7875-7880
33. Miyazaki T, Dierich A et al (1996) LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice. Int Immunol 8:725-729 (Pubitemid 26148294)
34. Moebius U, Pallai P et al (1993) Delineation of an extended surface contact area on human CD4 involved in class II major histocompatibility complex binding. Proc Natl Acad Sci USA 90:8259-8263 (Pubitemid 23260895)
35. Peggs KS, Quezada SA et al (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717-1725
36. Prigent P, El MS et al (1999) Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol 29:3867-3876
37. Rogala B, Gluck J et al (2002) Do the molecules CD26 and lymphocytes activation gene-3 differentiate between type 1 and 2 T cell response? J Investig Allergol Clin Immunol 12:198-203
38. Subramanyam M, Wands G et al (1998) Soluble human lymphocyte activation gene-3 modulates allospecific T cell responses. Int Immunol 10:679-689 (Pubitemid 28221469)
39. Triebel F, Jitsukawa S et al (1990) LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 171:1393-1405 (Pubitemid 20167538)
40. Triebel F, Hacene K et al (2006) A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 235:147-153
41. Woo SR, Li N et al (2010) Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol 40:1768-1777
42. Workman CJ, Vignali DA (2003) The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells, 1. Eur J Immunol 33:970-979 (Pubitemid 36546685)
43. Workman CJ, Dugger KJ et al (2002) Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3, 2. J Immunol 169:5392-5395 (Pubitemid 35291633)
44. Workman CJ, Cauley LS et al (2004) Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 172:5450-5455 (Pubitemid 38542045)
45. Workman CJ, Wang Y et al (2009) LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 182:1885-1891